# US 2024/0252237 A1 · Devices and methods for treating lung tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252237 A1
- Document ID: US20240252237A1
- Status: Published application
- Kind: A1
- Application number: 18/602,921
- Filed: 2024-03-12
- Published: 2024-08-01
- Earliest claimed: 2017-09-08
- Assignees: Zidan Medical, Inc.
- Applicants: Zidan Medical Inc.
- Inventors: Dorin PANESCU; Shashank RAINA; Mark Gelfand; Mark LEUNG; Simplicio VELILLA
- Web page: https://patentgrep.com/patent/US20240252237A1

## CPC

- A61B 18/1492: {having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence)}
- A61B 34/20: Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
- A61B 2018/0022: {Balloons}
- A61B 2018/00285: {Balloons}
- A61B 2018/00291: {using suction}
- A61B 2018/00541: {Lung or bronchi}
- A61B 2018/00577: {Ablation}
- A61B 2018/00642: {with feedback, i.e. closed loop control}
- A61B 2018/00648: {using more than one sensed parameter}
- A61B 2018/00702: {Power or energy}
- A61B 2018/00744: {Fluid flow}
- A61B 2018/00791: {Temperature}
- A61B 2018/00863: {Fluid flow}
- A61B 2018/00875: {Resistance or impedance}
- A61B 2018/00982: {combined with or comprising means for visual or photographic inspections inside the body, e.g. endoscopes}
- A61B 2018/048: {in gaseous form}
- A61B 2018/1425: {Needle}
- A61B 2018/1467: {using more than two electrodes on a single probe}
- A61B 2018/1472: {for use with liquid electrolyte, e.g. virtual electrodes}
- A61B 2034/2051: {Electromagnetic tracking systems}
- A61B 2034/2053: {Tracking an applied voltage gradient}
- A61B 2034/2061: {using shape-sensors, e.g. fiber shape sensors with Bragg gratings}
- A61B 2034/2063: {Acoustic tracking systems, e.g. using ultrasound}
- A61B 2090/306: {using optical fibres}
- A61B 2090/376: {using X-rays, e.g. fluoroscopy}
- A61B 2090/378: {using ultrasound}
- A61B 2090/3966: {Radiopaque markers visible in an X-ray image}
- A61B 2218/002: Irrigation
- A61B 2218/007: Aspiration
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

A method to treat a human patient including: advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung, injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the distal portion of the catheter into the target region; delivering energy from the distal portion into the conductive hypertonic saline solution in the target region, wherein the energy heats the liquid in the portion of the airway, and ablating the target region with the heated liquid.

## Claims

### Claim 1

A method to treat a human patient comprising:
advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung,
injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the distal portion of the catheter into the target region;
delivering energy from the distal portion into the conductive hypertonic saline solution in the target region, wherein the energy heats the liquid in the portion of the airway, and
ablating the target region with the heated conductive hypertonic saline solution.

### Claim 2 (depends on 1)

The method of claim 1, wherein the catheter is an endobronchial ablation catheter including a flexible shaft and the distal portion is on the flexible shaft, and
wherein the advancing the catheter includes advancing the flexible shaft through a trachea of the patient and a bronchus of the lung and into a bronchi of the lung extending into the target region.

### Claim 3 (depends on 1)

The method of claim 1, wherein the delivery of energy includes delivering radiofrequency electrical current from an ablation electrode on the distal portion of the catheter and into the conductive hypertonic saline solution.

### Claim 4 (depends on 1)

The method of claim 1, wherein the distal portion of the catheter includes an ablation electrode connectable to a source of radio frequency electrical current, a fluid outlet connectable to a source of the hypertonic saline solution, and an occluder proximal to the ablation electrode and the liquid outlet,
wherein the method further comprises expanding the occluder in the natural airway to obstruct the natural airway proximal to the target region.

### Claim 5 (depends on 4)

The method of claim 4, wherein a distance along the flexible shaft between the occluder and the ablation electrode is in a range of 5 to 40 mm.

### Claim 6 (depends on 4)

The method of claim 4, wherein the ablation electrode has a length in a range of 3 to 20 mm.

### Claim 7 (depends on 4)

The method of claim 4, wherein the ablation electrode is a first ablation electrode and the distal portion of the flexible shaft further comprises a second ablation electrode, wherein a distance between the first and second ablation electrodes along the distal portion is in a range of 5 to 15 mm.

### Claim 8 (depends on 1)

The method of claim 1, wherein the flexible shaft has an outer diameter less than 2 mm and is configured to bend to a radius of curvature of at least 7 mm.

### Claim 9 (depends on 1)

The method of claim 1, wherein the injecting of the conductive hypertonic saline solution injects no more than 20 ml of the conductive hypertonic saline solution into the target region.

### Claim 10 (depends on 9)

The method of claim 9, wherein the injecting of the conductive hypertonic saline solution is at a rate of no greater than 5 ml/min during the delivering of the energy.

### Claim 11

A method for treating a patient with lung cancer comprising:
advancing a catheter through a natural airway of a patient to a target region in a lung of the patient, wherein the target region has been identified as cancerous;
expanding an occlude in the natural airway, wherein the occluder is mounted to the catheter;
injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume of the hypertonic saline solution, and the hypertonic saline solution is injected from a fluid outlet in the catheter into the target region and the fluid outlet to the occluder;
delivering energy to the liquid in the portion of the airway wherein the energy heats the conductive liquid to a range of 75 degrees Celsius to 105 degrees Celsius, and
ablating the target region with the heated liquid in the portion of the airway.

### Claim 12 (depends on 11)

The method of claim 11, wherein the ablative thermal energy is delivered from an electrode on the catheter between the proximal and distal balloons, and the electrode is configured to emit radiofrequency energy to heat the liquid in the portion of the airway.

### Claim 13 (depends on 11)

The method of claim 11, further comprising compressing the lung at the target region prior to the injection of the hypertonic saline solution.

### Claim 14 (depends on 13)

The method of claim 13, wherein the compressing of the lung includes removing a fluid from the target region prior to the injection of the hypertonic saline solution.

### Claim 15 (depends on 13)

The method of claim 13, wherein the catheter is an endobronchial ablation catheter including a flexible shaft, and
wherein the advancing the catheter includes advancing the flexible shaft through a trachea of the patient and a bronchus of the lung, and into a bronchi of the lung extending to the target region.

### Claim 16 (depends on 11)

The method of claim 11, wherein the delivery of energy includes delivering radiofrequency (RF) electrical current from an ablation electrode on the catheter and into the conductive hypertonic saline solution injected into the target region.

### Claim 17 (depends on 11)

The method of claim 11, wherein the injecting of the conductive hypertonic saline solution injects no more than 20 ml of the conductive hypertonic saline solution into the target region.

### Claim 18 (depends on 17)

The method of claim 17, wherein the injecting of the conductive hypertonic saline solution is at a rate of no greater than 5 ml/min during the delivering of the energy.

### Claim 19

A method for treating a patent having a lung tumor comprising:
advancing an extended working channel of a bronchoscope transbronchially towards a natural airway of a lung of the patient;
advancing an ablation catheter from the extended working channel, through a bronchi of the natural airway and into the a target region of the lung including the lung tumor;
expanding a balloon on the ablation catheter to occlude the bronchi;
injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the catheter into the target region; and
delivering radiofrequency (RF) electrical current from an ablation electrode on the ablation catheter and into the conductive hypertonic saline solution at the target region to heat the hypertonic saline solution and ablate lung tissue in the target region.

### Claim 20 (depends on 19)

The method of claim 19, wherein the application of the RF electrical current the hypertonic saline solution to a range of 75 degrees Celsius to 105 degrees Celsius.

### Claim 21 (depends on 19)

The method of claim 19, further comprising compressing lung tissue at the target region immediately prior to the injection of the conductive hypertonic saline solution.

### Claim 22 (depends on 19)

The method of claim 19, wherein the ablation electrode has a length in a range of 3 to 20 mm.

### Claim 23 (depends on 19)

The method of claim 19, wherein the ablation electrode is a first ablation electrode and the distal portion of the flexible shaft further comprises a second ablation electrode, wherein a distance between the first and second ablation electrodes along the distal portion is in a range of 5 to 15 mm.

### Claim 24 (depends on 19)

The method of claim 19, wherein the ablation catheter has an outer diameter less than 2 mm and is configured to bend to a radius of curvature of at least 7 mm.

### Claim 25 (depends on 19)

The method of claim 19, wherein the injecting of the conductive hypertonic saline solution injects no more than 20 ml of the conductive hypertonic saline solution into the target region.

### Claim 26 (depends on 25)

The method of claim 25, wherein the injecting of the conductive hypertonic saline solution is at a rate of no greater than 5 ml/min during the delivering of the energy.
